DIAdvisor

The DIAdvisor is a large scale- integrating project (IP) aiming at development of a prediction based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes.

The DIAdvisor does not depend on specific sensor technologies and technologies like standard strip sensing, minimally invasive continuous glucose sensors and non-invasive methods.

For safety reason, the DIAdvisor system will be able to self-assess the confidence of its proposed decisions. For safety reasons as well as for the sake of therapy improvements the system connects and provides information and trends to the Health Care Provider.

Glucose prediction is difficult and requires advanced science. This can be achieved only by a well-balanced group of eminent experts including academics, clinicians, user representatives and leading companies. This includes physiological modelling, identification theory, control theory, medical device technology, risk management theory, sensor science and user understanding.

The expected impact of DIAdvisor will be improved diabetes control and quality of life in large populations of insulin treated patients, leading to fewer diabetic complications and lower Health Care costs. Moreover, the project will constitute a valuable opportunity for European companies to build up a special know-how leading products that profoundly and positively impacts the lives of millions with other indications than diabetes.

For further information, please visit:
http://www.diadvisor.eu/

Project co-ordinator:
Novo Nordisk A/S (Denmark)

Partners:

  • Novo Nordisk A/S (Denmark),
  • Johannes Kepler Universität Linz (Austria),
  • Lunds Universitet (Sweden),
  • Universita Degli Studi di Padova (Italy),
  • Centre Hospitalier Regional Universitaire de Montpellier (France),
  • Toumaz Technology Ltd (UK),
  • Sensor Technology and Devices Ltd (UK),
  • Ondalys SARL (France),
  • Romsoft SRL (Romania),
  • Institut Klinicke a Experimentalni Mediciny (Czech Republic),
  • RICAM, Österreichische Akademie der Wissenschaften (Austria),
  • Rambøll Danmark A/S (Denmark),
  • Federation Internationale du Diabete Region Europe (Belgium)

Timetable: from 03/2008 – to 02/2012

Total cost: € 9.284.061

EC funding: € 7.099.992

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...

OmicsFootPrint: Mayo Clinic's AI To…

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images. The details of the tool...

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

Testing AI with AI: Ensuring Effective A…

Using a pioneering artificial intelligence platform, Flinders University researchers have assessed whether a cardiac AI tool recently trialled in South Australian hospitals actually has the potential to assist doctors and...

AI Unlocks Genetic Clues to Personalize …

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes - insights that could help doctors tailor...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

Deep Learning to Increase Accessibility…

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...